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Abstract
Background: Methamphetamine, a highly addictive sympathomimetic stimulant, is currently widely abused
worldwide and has been associated with devastating effects on oral health, resulting in the term “meth mouth”.
However, “meth mouth” pathology is primarily based on case reports with a lack of systematic clinical evaluation.
Therefore, we have conducted a systematic study to investigate (1) the pharmacological impact of methamphetamine
on oral health with regard to saliva function, including the parameters saliva flow rate and total saliva production
(ml/5 min) and the buffering capacity of saliva; (2) the contribution of the symptoms of bruxism and muscle trismus to
potential oral health damage.
Methods: We assessed the data of 100 chronic methamphetamine abusers and 100 matched-pair comparison
participants. Primarily, we conducted an anamnesis with all methamphetamine abusers with regard to saliva
dysfunctions, jaw clenching and pain in the temporomandibular joint. Subsequently, in the first part of the clinical
enquiry, we tested the saliva flow rate and the total saliva production (ml/5 min) by using the sialometry method and
the buffer capacity of saliva by determining the pH-value. In the second part of the clinical enquiry, we evaluated
bruxism symptoms with respect to generalized tooth attrition, dentine exposure and visible enamel cracks and
examined a potential muscle trismus by measuring the maximal opening of the mouth.
Results: The majority of methamphetamine abusers reported a dry mouth (72 %) and jaw clenching (68 %). Almost
half of all methamphetamine abusers experienced pain in the temporomandibular joint (47 %). With regard to the
clinical findings, methamphetamine abusers showed significantly lower total saliva production (ml/5 min) (p < 0.001),
lower pH-values of their saliva (p < 0.001) and more bruxism symptoms (p < 0.001). However, we found no relevant
trismus symptoms on comparing the two groups (p > 0.05).
Conclusions: The sympathomimetic effects of chronic methamphetamine abuse may lead to dry mouth and
extensive bruxism and therefore can increase the risk for caries decay, periodontal lesions and tooth wear. Furthermore,
a significant decline of saliva buffer capacity in methamphetamine abusers may trigger the risk for dental erosions.
Methamphetamine abusers and practitioners should be aware of these symptoms.
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Background
Methamphetamine (MA) is a highly addictive stimulant
substance with deep historical roots. Originally, MA was
synthesized by Nagayoshi Nagai in Japan in 1893 [1].
During the Second World War, the substance received
political and military interest because of its disinhibiting
effect and, above all, because it increased vigilance. At
that time, the enormous potential of addiction to this
substance became evident. Consumption of MA causes
euphoria, subjectively stimulates performance and in-
creases a person’s sense of self-esteem. The need for
sleep and for assuaging hunger and thirst is reduced,
whereas sexual desire and the flow of words are in-
creased [1, 2]. These psychic and physical effects are
brought about by the stimulation of receptors of nor-
adrenalin and, in particular, of dopamine. MA prevents
the reabsorption of dopamine into the synaptic vesicles
and prolongs the effects of the substance in the synaptic
cleft [1].
Currently, the use of MA is rapidly spreading and MA
is widely abused with approximately 35 million MA
abusers around the globe [1]. In many parts of the
United States, MA seems to be replacing marijuana and
crack cocaine as “the drug of choice” [3]. In Europe, MA
is quickly expanding under the scene name of “Crystal”
or “Crystal Meth” (CM), particularly in Germany and
the Czech Republic. In a German Police Crime Statistic
of 2013, a CM rise of almost 200 % has been noted in
border areas to the Czech Republic during a two-year
comparison from 2010 to 2012. Simultaneously, in the
UK, the current abuse of CM is strongly increasing, par-
ticularly in London’s Gay Scene [4]. Individuals who
chronically use CM/MA run a high risk of experiencing
health hazards. However, MA use has particularly been
associated with a severe impact on oral health [5–9].
The sociological conditions of the US health-care system
led to the term “meth mouth” being coined in the
medical literature for the first time in 2005 [10]. The
pathogenic impact on oral health seems to be a pharma-
cological effect of methamphetamine. The substance is a
central nervous stimulant and a strong activator of the
sympathetic nervous system [1, 6]. These pharmaco-
logical effects can result in a dry mouth or even xerosto-
mia [11–13] with a subsequent higher risk for carious
lesions [14, 15], extensive grinding of the teeth [8, 10] or
jaw clenching and muscle trismus [9, 10, 16]. However,
“meth mouth’ symptoms and pathogenic mechanisms
found in the literature are primarily based on assump-
tions and individual case reports, with a lack of conclu-
sive relationships between chronic methamphetamine
abuse and the aforementioned symptoms. Systematic
study designs in this field are rare, mostly because of
problematic access to a suitable number of MA abusers.
Therefore, we have established a cooperation between
addiction and maxillofacial medicine in order to conduct
a systematic study comprising a large number of MA
abusers. We consider that the sympathomimetic effects
of the drug have a high impact on oral health. Hence,
the aim of this study has been to examine (1) the
pharmacological impact of MA on oral health with re-
gard to saliva function, including the parameters saliva
flow rate and total saliva production (ml/5 min) and the
buffering capacity of saliva; (2) the contribution of the




This cross-sectional study design involved cooperation
between two specialist clinics for addiction medicine in
Upper Franconia, Germany, the Department of Oral and
Maxillofacial Surgery of the Munich University of
Technology, Germany and the Institute for Medical
Biometry, Epidemiology and Medical Informatics of the
University of Saarland, Germany. With the close con-
sultation of each participating institution, the examining
scheme, the number of participants and an information
document setting out the objectives, risks and benefits
of the study were established in advance of the start of
the study. For the optimal comparability of data and the
verification of our clinical examination methods, we re-
cruited a comparison group including one same-aged
and same-gender participant for each MA abuser. In this
type of statistical comparison, defined as ‘matched-pair
analysis’, a study group and a comparison group are
made comparable with respect to extraneous factors by
pairing study participants and comparison group partici-
pants individually based on matched-pair criteria. By
matching study participants with a characteristic feature
(in our case chronic MA abuse) to similar participants
without this feature, matching enables a comparison of
outcomes among these two groups in order to estimate
the effect of the characteristic feature and to reduce bias
due to confounding. In order to provide the study with
adequate statistical power, a sample size calculation was
performed for one of the main parameters of this study,
namely ‘total saliva production (ml/5 min)’ (Table 2,
Fig. 2), in consultation with the Institute for Medical
Biometry, Epidemiology and Medical Informatics of
Saarland University, as follows: a sample size of 100 in
each group will have 80 % power to detect a difference
in means of −1.0 (the difference between a Group 1
mean, μ1, of 3.0 and a Group 2 mean, μ2, of 4.0) assum-
ing that the common standard deviation is 2.5 when a
two group t-test is used with a 0.05 two-sided signifi-
cance level. Therefore, the number of MA abusers and
of the comparison group participants was set at 100. All
study participants were provided with an information
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document setting out the objectives, risks and benefits
of the study. According to the requirements of the ethics
committee, we informed each participant about data use
and data protection and obtained his or her written con-
sent with regard to participation in the study. Our
methods were approved by the local ethics committee of
the Munich University of Technology (no. 5405/12)
and were in accordance with the 1964 Helsinki dec-
laration and its later amendments or comparable eth-
ical standards.
Participants
The selection and data acquisition of the 100 MA
abusers took place at the addiction clinics between April
2012 and October 2013. In the addiction clinics, an aver-
age of 30 MA abusers underwent clinical withdrawal
therapy for an average of 4 months with periodically
changing patients. Primarily, the executive psychother-
apist of each addiction clinic (2 psychotherapist overall)
performed a short patient interview with each MA
abuser in the clinic. The short patient interview included
an examination of the inclusion and exclusion criteria
and an explanation of the objectives, risks and benefits
of the study. First, the inclusion criteria were checked.
Inclusion criteria for the MA group included the con-
stant MA abuse of 1 g/week beyond a minimum period
of 12 months without any withdrawal periods (Table 1).
This definition of chronic MA abuse was determined in
consultation with the executive psychotherapists in the
addiction clinics based on their personal and long-term
experiences with chronic MA abusers and their addictive
behavior. If the inclusion criteria were fulfilled, the ex-
clusion criteria were checked. Exclusion criteria were de-
fined as the last MA abuse of longer than 1 month
previously and the excessive co-consumption of other
addictive substances to a similar extent to MA (Table 1).
If the MA abuser fulfilled the eligibility criteria, he or
she was provided with an information document setting
out the objectives, risks and benefits of the study, the ex-
ecutive psychotherapist being available in case of quer-
ies. Afterwards, each MA abuser was able to decide
independently whether he or she wanted to join the
study. 92 % of all questioned MA abusers agreed to par-
ticipate in the study. Subsequently, at fixed examination
appointments over 7-week periods on average, the clin-
ical examination of all participants, including a short
clinical anamnesis beforehand, was performed by a
dentist and a maxillofacial surgeon in a prepared sep-
arate room guaranteeing a quiet atmosphere. The ne-
cessary examination equipment was provided by the
Department of Oral and Maxillofacial Surgery of the
Munich University of Technology and brought to
each examination appointment.
For the comparison group, we defined the matched-
pair criteria gender and age (+/−1a). Participants for
the matched-pair group were selected from hospital-
ized patients at the University Hospital of the Munich
University of Technology and from patients of an ambula-
tory dental surgery in Augsburg, Germany. Hospitalized
patients at the University Hospital who had good general
health and no clinical abnormalities and who planned a
short in-patient stay of no longer than 1 day postopera-
tively were assessed for possible study participation. Oper-
ations planned on these patients were: 1. removal of
osteosynthesis plates after small midfacial or jaw fractures;
2. removal of odontogen cysts; 3. surgical extraction of
wisdom teeth. Group 1 had undergone a healing process
of, on average, 6 months after small fractures with no
complications during healing and with no persisting clin-
ical symptoms. Group 2 included patients with radiologic-
ally diagnosed cysts with no clinical symptoms. All
wisdom teeth of Group 3 were asymptomatic with no
Table 1 Participant data
MA group (n = 100) Comparison group (n = 100)
Inclusion criteria - Constant MA use over a minimum period of 1 year
- Constant MA use of 1 g/week by intranasal use,
smoking, intravenous use or swallowing
- Same gender as MA user
- Same age as MA user with a tolerance
of ±1 year
Exclusion criteria - Last MA use longer than 1 month ago
- <18th year of birth
- Excessive co-consumption of other addictive
substances to a similar extent to MA
-Any use of addictive substances in life
Recruitment and location of
examination
- Addiction Clinic in Hochstadt/Main, Germany (n = 76)
- Department of Addiction Medicine, Hospital for
Psychiatry, Psychotherapy, Psychosomatic Medicine,
Bayreuth, Germany (n = 24)
- Department of Oral and Maxillofacial Surgery,
Klinikum rechts der Isar, Munich, Germany
(n = 66)
- Dental surgery clinic, Augsburg, Germany
(n = 34)
Demographic characteristics - Mean age: 29.4 years (SD ± 7.4)
- Gender distribution: 83 males, 17 females
- Mean age: 29.3 years (SD ± 7.2 years)
- Gender distribution: 83 males, 17 females
Mean duration of MA use - 6.9 years (SD ± 4.6) - None
MA methamphetamine, SD standard deviation
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signs of inflammation. Therefore, these hospitalized pa-
tient groups could be equated with a generally healthy
study population. The examination of these patients was
always performed before the planned operation. Patients
at the ambulatory dental surgery with good general health
without intraoral wounds, feelings of pain, infections or
recently performed invasive therapies were assessed for
possible study participation. The scheme of examination
was the same in both comparison groups.
Data collection
Before the start of the clinical examination, every MA
abuser was asked, in a short clinical anamnesis, whether
he or she noticed following specific symptoms from the
beginning of MA abuse: 1. dry mouth; 2. jaw clenching;
3. pain in the temporomandibular joint (TMJ). If so, the
clinical symptoms were noted on the patient’s individual
examination form. The short clinical anamnesis was per-
formed by either the dentist or the maxillofacial surgeon.
As in the MA group, a short patient interview was per-
formed in the control group by either the dentist or the
surgeon. The structure of the interview was almost the
same as that of the MA group. First, the inclusion cri-
teria were examined (matched-pair criteria gender and
age). Subsequently, if the inclusion criteria were fulfilled,
the exclusion criteria were checked (any use of addictive
substances). If the potential study participant did not ful-
fil the exclusion criteria, the information document was
handed out combined with an informative conversation
with the either the dentist or the surgeon, if desired. If
the patient gave written consent, the clinical examin-
ation followed. 97 % of all questioned hospitalized and
ambulatory patients agreed to participate in the study.
The examination appointments of the comparison group
took place subsequent to and promptly after each exam-
ination appointment of the MA group. The complete
examination scheme is shown in Fig. 1.
In the first section of the clinical inquiry, the test per-
sons were initially screened for evidence of potential dry
mouth from chronic MA consumption. For this purpose,
measurements of the saliva flow rates and total saliva
production in milliliters within 5 min were taken by
using the sialometry method. Each test person was ad-
ministered a saliva-stimulating small paraffin wax cube
(CRT Paraffin, Vivadent Company, Ellwangen, Germany)
and requested to chew on it for 30 s. The test persons
were then asked to spit out the soft wax cubes and to
swallow all the saliva accumulated in the mouth. From
that time on, over a period of five minutes, the saliva
produced by the test persons was collected in a sterile
graduated measuring receptacle and immediately drawn
up into a 5 ml syringe and measured. Subsequently, the
total amount of saliva was noted. Subsequently, the indi-
vidual saliva buffering capacities were tested by means of
saliva samples. We used the CRT® buffer test (Vivadent
Company, Ellwangen, Germany), the test principle of
which included a determination of the pH-value of the
saliva. A pH-indicator was located on acid-treated test
sticks. A saliva sample from each participant was pipet-
ted onto a pH-indicator stick. If the saliva could buffer
the acids on this test stick, the colour of the indicator
stick changed. The grading of the buffer capacity was
indicated by five different degrees of change of colour
of the indicator surface after a response time of
exactly 5 min. The classification of the five different
degrees was carried out in accordance with the manu-
facture’s specifications of the test and as reported by
previous authors [17]. The complete first section of
the clinical examination with respect to saliva func-
tion was performed by the maxillofacial surgeon in all
study participants.
In the second section of the clinical inquiry, we evalu-
ated potential trismus and bruxism in connection with
chronic MA consumption. In order to assess potential
trismus, the patient was asked to open his/her mouth at
maximum angle. The cutting edge distance of the me-
dian upper jaw and lower jaw incisor were then marked
on a wooden spatula, measured up with a ruler and
noted as “maximum opening of the mouth” (MOM). For
evaluation of potential bruxism, the following criteria
were checked: 1. tooth attrition in more than 50 % of all
teeth, 2. dentine exposure through at least three occlusal
surfaces; 3. macroscopic visual enamel cracks in at least
three teeth. If a participant fulfilled at least one of these
three criteria, he or she was assessed as being positive
for bruxism. The complete second section of the clinical
examination was performed by the dentist in all study
participants.
Statistical methods
We used the software programs SPSS 23.0. (IBM,
Armonk, USA) and Cytel Studio version 10 (Cytel,
Cambridge, USA) for the statistical analysis and
Microsoft Excel 2010 (Microsoft, Redmond, USA) for
data transfer and handling. The complete data analysis
was performed in cooperation with the Institute for
Medical Biometry, Epidemiology and Medical Informatics
of the Saarland University, Germany. For each parameter,
an adequate statistical test was selected. p-values were
subject to a significance level of 0.05. For MOM and total
saliva production, we used the t-test for dependent sam-
ples by comparing means. For saliva buffer capacity, we
used the Wilcoxon signed-rank test for comparing me-
dians. For bruxism, we employed Mc Nemar’s test. The
two-sided level of significance was set at α = 0.05. Multiple
testing was accounted for by applying the procedure of
Bonferroni-Holm, i.e. by sorting p-values from the lowest
to the highest and comparison with the local adjusted
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significance level α/i, where i is the order of the respective
p-value pi.
Results
The majority of methamphetamine abusers reported a
dry mouth (72 %) and jaw clenching (68 %) from the
beginning of MA abuse. Almost half of all MA abusers
noticed pain in the TMJ (47 %). With respect to the clin-
ical examination, the total quantity of saliva was signifi-
cantly lower in the MA group in contrast to the
comparison group (p < 0.001). The median total quantity
of saliva of the MA group here was 1.8 ml (SD ± 1.2),
whereas in the comparison group, the average volume
was 4.1 ml (SD ± 2.7) of total saliva (Fig. 2). The ob-
served power calculation for the results of “total saliva
production” showed a 99 % power to detect a difference
in means of −2.3 by using a two group Satterthwaite
t-test with a 0.05 two-sided significance level. Among
the MA group, the buffer capacity (BC) of saliva was
also significantly lower (p < 0.001). Only 9 % had high
BC (pH above 6), 11 % medium-high (pH from 6–5.5) and
43 % medium BC (pH from 5.5–4.5); 30 % of MA con-
sumers displayed low-medium (pH from 4.5–4) and 7 %
low BC (pH below 4). Among the comparison group,
55 % revealed high, 25 % medium-high and 18 % medium
BC. Merely 3 % had low-medium BC; low BC was
Fig. 1 Examination scheme of all study participants
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not apparent among the comparison group. In the
MA group, the MOM averaged 48.7 mm (SD ± 6.6),
whereas in the comparison group, it was 48.1 mm
(SD ± 6.2). A statistically relevant difference could not
be discerned (p = 0.494). Bruxism criteria were ful-
filled among 81 % of MA consumers, whereas in the
comparison group, this percentage was only 39 %.
Thus, significant differences exist between the two groups
(p < 0.001). All clinical data are shown in Table 2.
Discussion
The results of the study indicate that sympathomimetic
effects of the substance MA contribute to the highly
damaging potential on the stomatognathic system in
cases of chronic MA abuse. We have found a signifi-
cantly lower saliva rate and significantly higher signs for
bruxism within the MA group in comparison with a
same-aged and same-gender group with no history of
MA abuse. Furthermore, chronic MA abuse reveals a
detrimental influence on saliva buffer capacity.
Many devastating effects of MA on oral health result-
ing in the term “meth mouth” are described in the
current literature [1, 8, 10, 13]. Dry mouth or even xer-
ostomia is one of the main symptom described in scien-
tific publications as occurring with chronic MA abuse
[11, 16] and with respect to “meth mouth” syndromes
[5, 8–10]. The mean standard stimulated salivation is
stated at 1–2 ml/min, with salivation of >0.7 ml/min be-
ing considered rather low [18]. In this study, the flow of
saliva averaged only 0.36 ml/min among 100 chronic
MA consumers. Furthermore, the majority of all MA
abusers experienced a dry mouth from the beginning of
MA abuse. Thus, we can confirm the symptom of a dry
mouth and the high risk potential of xerostomia in cases
of chronic MA abuse. Xerostomia is accompanied by the
loss of important protective features of saliva. Corres-
pondingly, the lack of salivation correlates with in-
creased caries incidence, gingivitis or periodontitis [19].
To a great extent, the reasons for a dry mouth or even
xerostomia induced by MA are still unknown. However,
the sympathomimetic essential effect of methampheta-
mine on the alpha-2-receptors of the brain is the main
reason for this [16]. The direct stimulation of the inhibi-
tory alpha-2-adrenal receptors of the salivary glands by
MA as a possible mechanism is, nevertheless, considered
to be controversial [11, 16]. In our study, we have not
Fig. 2 Mean stimulated total saliva production within 5 min in both groups (p < 0.001)
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evaluated the pathogenic mechanism of the symptom of
dry mouth but we consider that its development is a
composite of the factors described above. We have con-
firmed previous assumptions of a high risk for xerosto-
mia and subsequently caries decay in MA abusers.
These previous assumptions were primarily based on
case reports [5, 13]. We have detected only one system-
atic study involving the examination of salivary flow rate
and buffer capacity with 28 MA abusers and 16 com-
parison subjects; tooth wear was noted but no significant
decrease in saliva flow rates among the MA abusers
[20]. This study includes a small sample size, possibly
explaining the results being divergent from those of our
study. We have found a significant decline of saliva pro-
duction in the MA group; this is valuable information
for the development of specific preventive and thera-
peutic strategies in order to prevent a probable “meth
mouth” syndrome in MA abusers.
Saliva also plays an important part in the prevention
of erosive lesions [21, 22]. The erosion of enamel is facil-
itated when saliva flow rates and buffer capacity are low-
ered [21]. Under MA-influence, in particular, the pH of
saliva drops and the diminution of the buffer capacity
has been noticed [20, 23]. Navarro et al. examined the
effects of MA on saliva pH on the basis of eight test per-
sons who took a placebo or an MA derivative orally ac-
cording to a double-blind randomized study design [23].
In a comparison of the two groups after four hours, the
pH dropped by 0.6 in the group that had taken the MA
derivatives [23]. Ravenel et al. also compared saliva pH
and saliva buffer capacity between 28 MA consumers
and 16 healthy comparison test persons and found a
lower pH and lower saliva buffer capacities among the
MA group [20]. The results of our study also show a sig-
nificant lower saliva buffer capacity on MA consump-
tion. Together with the results of previous findings,
these data allow the conclusion to be made that saliva
pH drops and saliva buffer capacity is reduced with
chronic MA abuse. The underlying mechanism of action
of MA on the pH-value in the saliva and on the buffer
capacity has not been clarified adequately as yet and has
not been evaluated in this study. Presumably, reduced
salivation and its reasons are decisive factors, as max-
imum saliva buffer capacity is essentially achieved by
salivation [23].
Excessive neuromuscular activity among MA con-
sumers can cause parafunctional temporomandibular
function accompanied by intensified bruxism [24]. MA
consumers tend to clench and grind their teeth strongly
[8]. Trismus also frequently occurs because of excessive
neuromuscular activity on chronic MA consumption
[10]. Thus, parodontal diseases and temporomandibular
dysfunctions can be the consequences of permanent
bruxism and trismus [8]. In order to determine potential
trismus and bruxism, attention has been paid to poten-
tial painful restrictions in the opening of the mouth on
the basis of measurements of MOM and to the excessive
numbers of dental cut facets with possibly even dentine
exposure or enamel cracks. However, among the com-
parison group, the results of the maximum opening of
the mouth displays only slightly larger openings of the
mouth than among the MA group. This might be ex-
plained by the intensified neuromuscular activity causing
strong grinding, tenseness and trismus during acute
phases of consumption [8], whereas in phases of no con-
sumption, the “recovery” of masticatory muscles and,
thus, the reversibility of jawjoint symptoms might occur.
However, bruxism symptoms could be found in a
large number of patients (81 %) with a significant dif-
ference in comparison with the group without MA
abuse (p > 0.001). Moreover, the majority of MA
abusers reported jaw clenching and almost half of all
abusers indicated pain in the TMJ from the beginning
of MA abuse. These findings reveal a high risk for
enamel loss and tooth wear in cases of MA use like
and are in line with previous descriptions. In particu-
lar, the combination of bruxism and reduced saliva
buffer capacity, as also observed in the MA group,
might trigger the risk for dental erosions and enamel
loss significantly.
The findings of our study need to be viewed in context
with few limitations. Our evaluation of extensive grind-
ing facets in the bruxism part and the colour assessment
in the buffer capacity part of the study depends on the
examiner’s subjectivity. Furthermore, we had to rely on
the truthful answers of all study participants with regard
to inclusion and exclusion criteria. Despite these limita-
tions, the study concept and its findings show several
strengths including a systematic clinical evaluation in a
study population that is usually difficult to reach and for
which systematic study designs rarely exist. The large
sample size of this study provides high significance of
the examined parameters. Furthermore, the simultan-
eous examination of a matched-pair comparison group
guarantees optimal comparability of data and verifies
methods of data collection. In the future, additional re-
search involving systematic clinical intraoral examina-
tions, preferably with standardized indices and a
longitudinal study design, is recommended to confirm
the findings of this study and to gain a clearer view of
the “meth mouth” phenomenon.
Conclusion
In summary, the sympathomimetic central stimulant
MA has a strong impact on the stomatognathic system.
The findings of this study reveal significantly lower saliva
production in MA users; this might result in dry mouth
or even xerostomia in the long-term and, consequently,
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might increase the risk for oral diseases such as carious
lesions, oral tissue infections or erosions. Sympatho-
mimetic effects of MA lead to extensive jaw clenching
with tooth wear and loss of enamel. Additionally, MA
abusers show a worse saliva buffer capacity significantly,
whereby dental erosion will be favored. Based on the
aforementioned findings, the authors recommend spe-
cific preventive and therapeutic strategies in order to
avoid potential “meth mouth” syndrome and to support
the social rehabilitation of MA abusers.
Abbreviations
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Acknowledgements
The authors would like thank Annegret Sievert for assistance with acquiring
participants; Stefanie Lukas for the organization of research instruments and
Theresa Jones for the final language correction of the manuscript.
Funding
This study was supported by internal funding sources of the Department of
Oral and Maxillofacial Surgery, Munich University of Technology.
Availability of data and materials
The individual data will not be made available in order to protect the
participant’s identity.
Authors’ contributions
The study concept was developed by MK, NRH, NR and RP. MK, NHR, NR and
RP developed the questionnaire and clinical methods. RP, NR and NHR
recruited participants and collected data. The complete statistical analysis
was performed by SW. NR and SK wrote the first draft of the paper and all




The authors declare that they have no competing interests.
Consent to publication
Not applicable, because each participant was pseudonymized by a code
number.
Ethics approval and consent to participate
This study was conducted with the approval of the Ethics Committee of the
Munich University of Technology (no. 5405/12). We informed each
participant about data use and data protection and obtained his or her
written consent with regard to participation in the study.
Author details
1Department of Oral and Maxillofacial Surgery, Klinikum rechts der Isar,
Technische Universität München, Ismaninger Str. 22, Munich D-81675,
Germany. 2Institute for Medical Biometry, Epidemiology and Medical
Informatics, Saarland University, Campus Homburg, Kirrberger Straße 100,
Homburg D-66424, Germany. 3Department of Addiction Medicine, Hospital
for Psychiatry, Psychotherapy, Psychosomatic Medicine, and Neurology,
Nordring 2, D-954, 44 Bayreuth, Germany.
Received: 12 October 2015 Accepted: 19 May 2016
References
1. Hamamoto DT, Rhodus NL. Methamphetamine abuse and dentistry. Oral Dis.
2009;15:27–37.
2. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook.
20th ed. Hudson: Lexi-Comp, Inc.; 2011.
3. Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and
amphetamine abuse in North America: a review of the indicators,
1992–2007. Drug Alcohol Rev. 2008;27:229–35.
4. Kirby T, Thornber-Dunwell M. High-risk drug practices tighten grip on
London gay scene. Lancet. 2013;381:101–2.
5. Naidoo S, Smit D. Methamphetamine abuse: a review of the literature and
case report in a young male. SADJ. 2011;66:124–7.
6. Donaldson M, Goodchild JH. Oral health of the methamphetamine abuser.
Am J Health Syst Pharm. 2006;63:2078–82.
7. Rhodus NL, Little JW. Methamphetamine abuse and “meth mouth”. Pa Dent
J (Harrisb). 2008;75:19–29.
8. Curtis EK. Meth mouth: a review of methamphetamine abuse and its oral
manifestations. Gen Dent. 2006;54:125–9. quiz 30.
9. Heng CK, Badner VM, Schiop LA. Meth mouth. N Y State Dent J. 2008;74:50–1.
10. Rhodus NL, Little JW. Methamphetamine abuse and “meth mouth”.
Northwest Dent. 2005;84:29, 31, 3–7.
11. Saini T, Edwards PC, Kimmes NS, Carroll LR, Shaner JW, Dowd FJ. Etiology of
xerostomia and dental caries among methamphetamine abusers. Oral
Health Prev Dent. 2005;3:189–95.
12. Shaner JW, Kimmes N, Saini T, Edwards P. “Meth mouth”: rampant caries in
methamphetamine abusers. AIDS Patient Care STDs. 2006;20:146–50.
13. Turkyilmaz I. Oral manifestations of “meth mouth”: a case report. J Contemp
Dent Pract. 2010;11:E073–80.
14. Goodchild JH, Donaldson M. Methamphetamine abuse and dentistry: a
review of the literature and presentation of a clinical case. Quintessence Int.
2007;38:583–90.
15. Brown RE, Morisky DE, Silverstein SJ. Meth mouth severity in response to
drug-use patterns and dental access in methamphetamine users. J Calif
Dent Assoc. 2013;41:421–8.
16. Shaner JW. Caries associated with methamphetamine abuse. J Mich Dent
Assoc. 2002;84:42–7.
17. Kitasako Y, Moritsuka M, Foxton RM, Ikeda M, Tagami J, Nomura S.
Simplified and quantitative saliva buffer capacity test using a hand-held pH
meter. Am J Dent. 2005;18:147–50.
18. Hellwig E, Klimek J, Attin T. Introduction to restorative dentistry. 3rd ed.
Munich: Urban & Fischer; 2003.
19. Fox PC. Xerostomia: recognition and management. Dent Assist. 2008;77:18, 20,
44–8; quiz 50–1.
20. Ravenel MC, Salinas CF, Marlow NM, Slate EH, Evans ZP, Miller PM.
Methamphetamine abuse and oral health: a pilot study of “meth mouth”.
Quintessence Int. 2012;43:229–37.
21. Buzalaf MA, Hannas AR, Kato MT. Saliva and dental erosion. J Appl Oral Sci.
2012;20:493–502.
22. Amaechi BT, Higham SM. Eroded enamel lesion remineralization by saliva as
a possible factor in the site-specificity of human dental erosion. Arch Oral
Biol. 2001;46:697–703.
23. Navarro M, Pichini S, Farre M, Ortuno J, Roset PN, Segura J, de la Torre R.
Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine
and its metabolites: correlation with plasma drug concentrations and effect of
salivary pH. Clin Chem. 2001;47:1788–95.
24. McGrath C, Chan B. Oral health sensations associated with illicit drug abuse.
Br Dent J. 2005;198:159–62; dicussion 47; quiz 74.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Rommel et al. BMC Oral Health  (2016) 16:59 Page 8 of 8
